Published in Br J Haematol on April 01, 2001
Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol (2006) 2.41
Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol (2003) 1.58
Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J Clin Microbiol (2003) 1.49
Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol (2004) 1.28
In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol (2006) 1.16
Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol (2004) 1.08
Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J Clin Microbiol (2013) 1.04
Semiquantitative detection by real-time PCR of Aspergillus fumigatus in bronchoalveolar lavage fluids and tissue biopsy specimens from patients with invasive aspergillosis. J Clin Microbiol (2003) 1.03
Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. J Clin Microbiol (2006) 1.02
Rapid differentiation of Aspergillus species from other medically important opportunistic molds and yeasts by PCR-enzyme immunoassay. J Clin Microbiol (2004) 0.98
The polypore mushroom Irpex lacteus, a new causative agent of fungal infections. J Clin Microbiol (2005) 0.88
Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections. Curr Fungal Infect Rep (2013) 0.87
Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate. Clin Diagn Lab Immunol (2005) 0.86
Invasive fungal infections in acute leukemia. Ther Adv Hematol (2011) 0.86
Analysis of performance of a PCR-based assay to detect DNA of Aspergillus fumigatus in whole blood and serum: a comparative study with clinical samples. J Clin Microbiol (2011) 0.85
Polymerase chain reaction screening for fungemia and/or invasive fungal infections in patients with hematologic malignancies. Support Care Cancer (2006) 0.80
Early Diagnosis of Invasive Aspergillosis in Neutropenic Patients. Comparison between Serum Galactomannan and Polymerase Chain Reaction. Clin Med Insights Oncol (2010) 0.80
Surgery of pulmonary aspergillomas in immunocompromised patients. Thorac Surg Sci (2010) 0.75
Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol (1997) 5.86
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet (2000) 3.18
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol (2000) 3.02
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78
Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet (2001) 2.77
Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett (1997) 2.72
Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol (1999) 2.33
In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother (1998) 2.32
Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b. Infect Immun (1985) 2.25
Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci U S A (1975) 2.21
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15
Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood. J Clin Microbiol (1997) 2.13
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (2009) 2.00
Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci U S A (1997) 1.98
Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature (1985) 1.98
Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet (2000) 1.94
Contaminations occurring in fungal PCR assays. J Clin Microbiol (1999) 1.86
Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet (1996) 1.85
Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant (2005) 1.79
Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant (2008) 1.78
Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis (1998) 1.77
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med (1991) 1.71
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Detection of PCR-amplified fungal DNA by using a PCR-ELISA system. Med Mycol (1998) 1.61
Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol (2000) 1.60
Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis (1998) 1.58
Qualitative and quantitative assessment of C3-receptor reactivities on lymphoid and phagocytic cells. J Immunol (1981) 1.57
CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol (2004) 1.57
Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis (1997) 1.57
High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer (2008) 1.56
Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant (2008) 1.56
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant (2006) 1.53
Distribution of human endogenous retrovirus HERV-K genomes in humans and different primates. Hum Genet (1995) 1.52
[Vancomycin resistant enterococci in Austria]. Wien Klin Wochenschr (1997) 1.51
Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother (2001) 1.50
Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine (1992) 1.47
Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis (2000) 1.47
Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI). Bone Marrow Transplant (2007) 1.46
Acquisition of host cell-surface-derived molecules by HIV-1. AIDS (1996) 1.46
Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta- lactamase: parallel outbreaks due to multiple plasmid transfer. J Clin Microbiol (1996) 1.45
Cytokine-induced generation of multinucleated giant cells in vitro requires interferon-gamma and expression of LFA-1. Eur J Immunol (1990) 1.44
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant (2009) 1.44
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi. Med Microbiol Immunol (1997) 1.44
Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant (2009) 1.42
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant (2004) 1.40
The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem J (1998) 1.40
Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation (2001) 1.39
A new kind of orphan drug? Nature (1992) 1.38
Demonstration of binding sites for IgG Fc and the third complement component (C3) on isolated hepatocytes. J Immunol (1976) 1.36
Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis (2009) 1.35
Urinary tract infection caused by nontyphoidal Salmonella: report of 30 cases. Urol Int (1992) 1.33
Enzyme-linked immunosorbent assay for detection of T-2 toxin. Hoppe Seylers Z Physiol Chem (1982) 1.33
Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR. J Clin Microbiol (2000) 1.33
TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol (2008) 1.32
Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis (1998) 1.31
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology (2001) 1.31
Simultaneous infection with two drug-susceptible Mycobacterium tuberculosis strains in an immunocompetent host. J Clin Microbiol (1999) 1.29
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis (2001) 1.29
The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun (1999) 1.29
HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. AIDS (1992) 1.29
The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun (2002) 1.28
Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant (2009) 1.28
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant (2000) 1.26
Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant (2005) 1.25
Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int (1992) 1.25
In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother (2001) 1.24
Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2003) 1.24
Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J (1985) 1.24
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol (2006) 1.23
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology (2000) 1.23
Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med (1996) 1.23
Comparative study of five different techniques for epidemiological typing of Escherichia coli O157. Diagn Microbiol Infect Dis (1998) 1.22
Diagnosis of invasive fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 1.21
Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect (2000) 1.21
Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol (2000) 1.20
Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood (1997) 1.20